<DOC>
	<DOCNO>NCT01134341</DOCNO>
	<brief_summary>This study design determine recommend dose , safety , pharmacokinetics , early efficacy combination pralatrexate plus oral bexarotene patient relapse refractory CTCL .</brief_summary>
	<brief_title>Pralatrexate Bexarotene Patients With Relapsed Refractory Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Lymphoma , Primary Cutaneous Anaplastic Large Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Cutaneous Tcell lymphoma patient subtypes mycosis fungoides ( MF ) Stage IB high , SÃ©zary syndrome , primary cutaneous anaplastic large cell lymphoma fail previous systemic treatment . Patients must receive least 1 previous systemic therapy , either progress tolerate last prior treatment regimen . Eastern Cooperative Oncology Group Performance Status less equal 2 . Adequate blood , liver , kidney function define laboratory test . Women childbearing potential must practice medically acceptable contraception study treatment start least 30 day last dose study treatment . Negative serum pregnancy test within 14 day first day study treatment ( required patient postmenopausal least 1 year surgically sterilize ) . Study treatment give woman breastfeed . Males sexually active must agree practice medically acceptable barrier contraception receive study treatment 30 day last dose study treatment . Give write informed consent &amp; privacy authorization . If history prior malignancy nonmelanoma skin cancer , carcinoma situ cervix , localized prostate cancer , localize thyroid cancer , patient must disease free least 5 year . Patients prior malignancy less 5 year study entry may enrol receive treatment result complete resolution cancer current clinical , radiologic , laboratory evidence active recurrent disease . Human immunodeficiency virus ( HIV ) positive diagnosis CD4 count le 100 mm3 detectable viral load within past 3 month , receive combination antiretroviral therapy . Diagnosis Hepatitis B virus , Hepatitis C virus detectable viral load immunological evidence chronic active disease receiving/requiring antiviral therapy . Active central nervous system disease require treatment . Active uncontrolled infection , underlie medical condition , serious illness impair patient 's ability receive protocol treatment . Discontinuation prior oral bexarotene due allergic reaction treatmentrelated toxicity . Major surgery within 2 week plan start treatment . Conventional investigational chemotherapy radiation therapy encompass great 10 % bone marrow within 4 week prior study treatment . ECP , phototherapy PUVA , ultraviolet ( UV ) therapy within 2 week prior study treatment . Systemic corticosteroid within 3 week study treatment , unless patient take continuous dose 10 mg per day prednisone equivalent least 4 week . Initiation change dosage topical corticosteroid within 3 week study treatment ( topical steroid use within 3 week allow provided strength use stable least 4 week ) . Investigational drug , biologics , device use within 2 week prior study treatment plan use study . Monoclonal antibody within 3 month without evidence PD . Use oral retinoids , except bexarotene , within 4 week study treatment highdose vitamin A ( daily multivitamin allow ) . Previous exposure pralatrexate . Uncontrolled hypercholesterolemia hypertriglyceridemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>